HAVCR2 and acute myeloid leukemia: Effective CAR‐T therapies are being developed one after another, and some studies have shown that CD13 and TIM3 bispecific CAR‐T cells have a better killing effect on AML, and also reduce the cytotoxicity of stem cells and peripheral myeloid cells.84